Search

Displaying results 41 - 50 of 108 in total
  1. Indication

    Clear Cell Renal Cell Carcinoma

    go.drugbank.com/conditions/DBCOND0029155
    Drugs: Belzutifan · Pembrolizumab
  2. Indication

    Metastatic Merkel Cell Carcinoma (MCC)

    go.drugbank.com/conditions/DBCOND0093764
    Drugs: Avelumab · Pembrolizumab
  3. Indication

    Recurrent, locally advanced Merkel Cell Carcinoma

    go.drugbank.com/conditions/DBCOND0144323
    Drugs: Pembrolizumab · Retifanlimab
  4. Indication

    Relapsed Classical Hodgkin's Lymphoma

    go.drugbank.com/conditions/DBCOND0144295
    Drugs: Nivolumab · Pembrolizumab
  5. Indication

    Unresectable Mismatch Repair Deficient Colorectal Cancer

    go.drugbank.com/conditions/DBCOND0144309
    Drugs: Nivolumab · Pembrolizumab
  6. Drug

    Vibostolimab

    go.drugbank.com/drugs/DB16420
    Investigational

    Vibostolimab is under investigation in clinical trial NCT04303169 (Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With

  7. Indication

    Nonsmall Cell Lung Cancer, Stage II

    go.drugbank.com/conditions/DBCOND0129475
    Drugs: Atezolizumab · Pembrolizumab
  8. Indication

    Advanced Microsatellite Instability High Endometrial Carcinoma

    go.drugbank.com/conditions/DBCOND0147954
    Drugs: Dostarlimab · Pembrolizumab
  9. Indication

    Metastatic Microsatellite Instability High Colorectal Cancer

    go.drugbank.com/conditions/DBCOND0144308
    Drugs: Nivolumab · Pembrolizumab
  10. Indication

    Metastatic Adenocarcinoma of the Gastroesophageal Junction

    go.drugbank.com/conditions/DBCOND0069248
    Drugs: Pembrolizumab · Trastuzumab